HIV / AIDS

Boston’s Fenway Health looked at testing and prevention trends during 3 phases of the COVID-19 pandemic.

Urgent efforts are needed to speed the process for HIV testing among children living with HIV in sub-Saharan Africa and countries with a high HIV burden, the study authors said.

For the first time, investigators from the Wistar Institute created a DNA-based vaccine that successfully produced tier-2 antibodies capable of neutralizing HIV in mice.

Investigators modeled what a long-acting injectable HIV prevention medication would have to cost in order for it to be justified when compared to generic, oral PrEP for HIV patients and transmission prevention.

The VB variant likely originated in the late 1990s, and if left untreated, is more transmissible and deadly than prior HIV strains.

The first study to estimate rates of undiagnosed HIV in children across sub-Saharan Africa found significant gaps in HIV testing.

States that required ongoing medical doctor supervision of nurse practitioners and physician assistants had fewer HIV PrEP prescriptions.

Researchers could be one step closer to an HIV vaccine. This one uses mRNA technology.

The FDA label expansion means adults living with HIV can now receive an injection of cabotegravir and rilpivirine (Cabenuva) once every 2 months instead of once monthly.

The study authors focused on eastern Europe and central Asia in their model, which included 4 scenarios for decriminalizing drug use and investing the savings into HIV transmission-reduction strategies.

The first doses of Moderna and IAVI’s mRNA HIV vaccine have been administered in the phase 1 IAVI G002 clinical trial.

Providers of patients with HIV should have greater sensitivity to symptoms of heart failure, the study authors suggested.

The study authors observed reductions in three types of orphanhood, including paternal-only, maternal-only, and double orphanhood.

In utilizing a modeling study, investigators estimated reductions in HIV incidence rates as well as PrEP usage rates and viral suppression across US cities over 10 years.

Investigators used an updated “kick and kill” strategy to expose and eliminate dormant infected cells in HIV-positive mice.

There is a high level of engagement in HIV care observed among pregnant women, which displays a commitment to their health and wellbeing during their pregnancy, the study authors wrote.

The AIDS Clinical Trials Group (ACTG) is beginning stage 2 trials for Triplex, a novel vaccine for people living with HIV and cytomegalovirus (CMV).

By 2030, the US is targeting reducing the number of new HIV infections by 90 percent.

Dolutegravir-based antiretroviral therapy proved more effective than standard treatments for HIV-positive children, reducing treatment failure by 40%.

Investigators compared pre- and post-intervention data points at 4 clinics in Kenya.

Stigma, and a lack of communication and awareness all inhibit HIV PrEP uptake, but digital health and new forms of PrEP are aiming to increase users.

This novel therapeutic option represents the first long-acting injectable approved for maintenance of HIV-1 suppression.

The therapy becomes the first injectable approved in the United States for this indication.

Nearly 20% of infants were overweight or obese by 1 year of age regardless of HIV exposure, a new study in South Africa found.

The proposed funding will include a number of measures of spending towards HIV and prevention, including community centers for PrEP education.

A clinical trial of 8 sub-Saharan African countries will be the first to study the efficacy of mRNA COVID-19 vaccination in people living with HIV.

A novel digital pill was 98% effective in tracking daily HIV PrEP adherence.

Community-based models of antiretroviral therapy were as effective as facility-based care in terms of viral suppression, the study authors wrote.

The CDC updated its HIV PrEP guidelines, including a recommendation that doctors talk to all sexually active adults about HIV prevention and prescribe PrEP to anyone who asks for it.

Urban areas in Florida had more social disorganization factors that drove HIV incidence than rural areas.